middl
east
respiratori
syndrom
mer
acut
respiratori
diseas
caus
mer
coronaviru
merscov
first
case
confirm
saudi
arabia
sinc
case
primarili
occur
countri
near
arabian
peninsula
typic
symptom
mer
fever
cough
short
breath
often
accompani
pneumonia
also
sometim
accompani
digest
symptom
diarrhea
clinic
manifest
merscov
infect
rang
asymptomat
infect
pneumonia
acut
respiratori
distress
syndrom
even
multiorgan
failur
result
death
major
patient
diseas
progress
rapidli
pneumonia
within
week
symptom
onset
mechan
ventil
intens
care
treatment
often
requir
merscov
zoonot
viru
transmit
anim
human
major
reservoir
host
thought
dromedari
camel
humantohuman
transmiss
known
commonli
http
infect
chemoth
wwwicjournalorg
occur
humantohuman
transmiss
occur
usual
result
close
contact
mer
patient
either
within
famili
within
healthcar
facil
august
total
confirm
patient
merscov
infect
worldwid
die
mortal
rate
vast
major
case
occur
saudi
arabia
republ
korea
sinc
first
confirm
mer
patient
return
saudi
arabia
may
total
confirm
case
infect
hospit
outbreak
date
august
patient
die
mortal
rate
domest
merscov
epidem
concern
mortal
would
high
henc
korean
societi
infecti
diseas
ksid
korean
societi
chemotherapi
ksc
collabor
produc
distribut
simpl
recommend
use
antivir
drug
base
antivir
treatment
data
previou
epidem
sever
acut
respiratori
syndrom
coronaviru
sarscov
similar
merscov
recent
data
treatment
merscov
south
korean
merscov
epidem
termin
compil
antivir
merscov
treatment
guidelin
base
recent
domest
experi
treat
patient
mer
effort
achiev
effect
mer
treatment
futur
present
treatment
guidelin
address
merscov
antivir
drug
certain
adjuv
treatment
help
treatment
patient
mer
also
plan
publish
guidelin
diagnosi
infect
control
merscov
discuss
present
guidelin
addit
use
prophylact
antivir
drug
merscov
exposur
address
guidelin
due
lack
relat
evid
patient
target
antivir
treatment
guidelin
adult
includ
pregnant
women
elderli
inform
intend
use
gener
specialist
practition
treat
patient
mer
juli
guidanc
korean
societi
infecti
diseas
ksid
korean
societi
chemotherapi
ksc
committe
develop
antivir
merscov
treatment
guidelin
form
includ
five
specialist
physician
infecti
diseas
nine
key
question
antivir
drug
adjuv
treatment
select
follow
collect
evalu
evid
relat
treatment
merscov
similar
viru
sarscov
well
review
oversea
merscov
treatment
guidelin
perform
search
literatur
relat
merscov
sarscov
treatment
guidelin
publish
search
literatur
past
year
detail
dose
advers
effect
antivir
drug
includ
interferon
ribavirin
lopinavirritonavir
search
perform
pubm
wwwpubmedgov
use
combin
follow
search
term
middl
east
respiratori
syndrom
sever
acut
respiratori
syndrom
coronaviru
treatment
therapi
antivir
number
origin
articl
merscov
treatment
small
review
articl
includ
case
report
determin
strength
evid
recommend
follow
guidelin
infecti
diseas
societi
america
minor
modif
tabl
written
recommend
key
question
determin
panel
confer
among
five
specialist
key
recommend
decid
sent
email
committe
guidelin
develop
well
extern
infecti
diseas
specialist
assess
appropri
recommend
scale
follow
review
result
issu
rais
rec
tabl
recommend
evidentiari
strength
qualiti
alway
offer
one
properli
design
random
control
trial
b
gener
offer
ii
one
welldesign
nonrandom
trial
cohort
casecontrol
analyt
studi
prefer
one
center
dramat
result
uncontrol
experi
although
role
antivir
treatment
mer
similar
diseas
sar
clearli
proven
consid
high
mortal
morbid
rate
antivir
treatment
consid
addit
appropri
support
care
biii
import
risk
factor
predict
progress
sever
diseas
death
includ
old
age
underli
diseas
cardiac
diseas
chronic
pulmonari
diseas
diabet
chronic
renal
diseas
etc
breath
difficulti
bilater
pneumonia
ii
risk
factor
present
confirm
suspect
merscov
case
activ
antivir
treatment
recommend
biii
even
patient
without
risk
factor
relat
progress
sever
diseas
death
respiratori
failur
multiorgan
failur
may
develop
rapidli
iii
therefor
patient
suspect
confirm
merscov
infect
symptom
fever
short
breath
pulmonari
infiltr
chest
xray
antivir
treatment
recommend
long
risk
advers
effect
high
biii
sar
epidem
antivir
ribavirin
lopinavirritonavir
use
larg
number
patient
result
report
cohort
studi
howev
clear
conclus
efficaci
antivir
seriou
lack
clinic
data
demonstr
effect
antivir
treatment
patient
mer
data
exist
deriv
retrospect
cohort
studi
includ
small
number
patient
show
clear
therapeut
effect
one
retrospect
studi
analyz
effect
antivir
treatment
patient
mer
surviv
rate
treatment
group
significantli
higher
control
group
vs
p
signific
differ
surviv
vs
p
howev
patient
mer
show
high
mortal
rate
approxim
report
middl
east
south
korean
epidem
antivir
treatment
activ
consid
sinc
efficaci
confirm
laboratori
studi
shown
degre
efficaci
retrospect
clinic
studi
merscov
infect
import
risk
factor
factor
death
old
age
year
depend
studi
underli
diseas
cardiac
diseas
chronic
pulmonari
diseas
diabet
chronic
renal
diseas
etc
bilater
pneumonia
low
cycl
threshold
c
valu
realtim
revers
transcript
polymeras
chain
reaction
diagnosi
risk
factor
predict
progress
sever
diseas
also
similar
data
analyz
patient
south
korean
epidem
age
year
short
breath
signific
risk
factor
multivari
analysi
univari
analysi
underli
diseas
bilater
pneumonia
also
associ
death
unpublish
data
retrospect
studi
omrani
et
al
antivir
treatment
significantli
improv
surviv
patient
sever
mer
requir
mechan
ventil
therefor
patient
risk
factor
death
progress
sever
mer
activ
antivir
treatment
recommend
retrospect
cohort
studi
shown
also
case
healthi
medic
worker
patient
without
underli
diseas
die
progress
sever
diseas
analysi
domest
patient
mer
show
death
two
patient
without
particular
underli
diseas
unpublish
data
therefor
even
patient
without
underli
diseas
clear
symptom
sign
pneumonia
antivir
treatment
consid
long
risk
advers
effect
consid
high
antivir
administr
consid
soon
possibl
diagnosi
biii
retrospect
studi
effect
antivir
treatment
merscov
infect
highli
like
therapeut
effect
antivir
unclear
major
patient
critic
ill
due
sever
pneumonia
multiorgan
failur
also
look
sever
observ
studi
sarscov
treatment
therapeut
effect
report
antivir
treatment
ribavirin
start
day
onset
symptom
therapeut
effect
report
antivir
administ
within
hour
hospit
sar
diagnosi
consid
fact
therapeut
effect
antivir
merscov
expect
treatment
administ
soon
possibl
diagnosi
combin
regimen
type
interferon
ribavirin
lopinavirritonavir
recommend
antivir
therapi
biii
use
ribavirin
alon
recommend
antivir
therapi
wherea
combin
administr
type
interferon
recommend
aiii
case
difficult
use
ribavirin
antivir
therapi
combin
regimen
type
interferon
lopinavirritonavir
consid
first
aiii
dose
ribavirin
merscov
treatment
standard
drug
use
dose
previou
clinic
trial
treatment
respiratori
virus
dose
adjust
may
requir
patient
show
sign
declin
renal
function
aiii
tabl
current
antivir
drug
clearli
proven
clinic
effect
treatment
merscov
infect
antivir
studi
report
date
mostli
laboratori
studi
actual
clinic
data
use
antivir
limit
data
anim
experi
small
amount
clinic
data
type
interferon
ribavirin
lopinavirritonavir
type
interferon
includ
anim
experi
rhesu
macaqu
combin
regimen
ribavirin
show
clinic
improv
reduc
sever
clinic
case
report
patient
improv
combin
therapi
ribavirin
howev
room
remain
debat
due
lack
suffici
clinic
studi
combin
therapi
use
type
interferon
ribavirin
one
retrospect
compar
analysi
case
treat
ribavirin
neither
regimen
effect
anoth
retrospect
clinic
studi
effect
combin
regimen
ribavirin
patient
receiv
treatment
surviv
beyond
day
wherea
seven
patient
nontreat
group
surviv
seemingli
demonstr
effect
combin
regimen
p
howev
interpreta
studi
limit
abil
provid
statist
proof
due
small
number
patient
howev
sinc
overal
trend
improv
type
interferon
ribavirin
combin
therapi
group
lack
effect
shown
conclus
combin
therapi
recommend
evid
use
lopinavirritonavir
antivir
merscov
infect
base
efficaci
treatment
sarscov
anim
experi
common
marmoset
administr
lopinavirritonavir
alon
significantli
reduc
number
merscov
coloni
lung
compar
nontreat
group
effect
ident
inde
one
report
show
patient
administ
lopinavirritonavir
time
type
interferon
ribavirin
combin
therapi
show
improv
viremia
day
henc
possibl
use
lopinavirritonavir
addit
type
interferon
ribavirin
combin
therapi
recommend
type
interferon
vitro
studi
show
stronger
effect
moreov
option
median
effect
inhibitori
concentr
ec
maximum
serum
concentr
ratio
lower
howev
clinic
studi
lack
particular
type
interferon
yet
conclud
superior
other
one
vitro
studi
ribavirin
separ
inhibit
merscov
prolifer
howev
merscov
prolifer
inhibit
typic
concentr
ribavirin
use
clinic
inhibit
confirm
concentr
show
toxic
human
therefor
monotherapi
ribavirin
typic
dose
expect
show
reduc
clinic
effect
nevertheless
ribavirin
administ
combin
show
synergist
effect
reduc
dose
ribavirin
requir
therefor
combin
administr
interferon
recommend
mention
lopinavirritonavir
compar
interferon
anim
experi
common
marmoset
henc
case
ribavirin
use
due
renal
dysfunct
advers
effect
monotherapi
lopinavirritonavir
consid
nevertheless
sinc
still
antivir
clearli
proven
clinic
effect
treatment
merscov
infect
long
contraind
combin
regimen
type
interferon
lopinavirritonavir
first
consid
studi
dosedepend
differ
therapeut
efficaci
ribavirin
treatment
merscov
infect
henc
dose
use
retrospect
studi
omrani
et
al
recommend
dose
typic
use
sarscov
treatment
howev
concern
ribavirininduc
advers
effect
includ
cytopenia
hemolyt
anemia
reduc
dose
could
use
reduc
dose
base
synergist
effect
combin
type
interferon
ribavirin
vitro
studi
follow
dose
use
treatment
respiratori
syncyti
viru
ensur
safeti
nevertheless
sinc
suppress
viru
prolifer
show
dosedepend
pattern
vitro
studi
dose
choic
need
care
consid
dose
adjust
requir
ribavirin
accord
renal
function
creatinin
clearanc
crcl
requir
monitor
throughout
treatment
increas
risk
advers
effect
renal
function
declin
care
must
taken
antivir
treatment
gener
recommend
day
patient
merscov
infect
biii
antivir
treatment
previous
administ
day
patient
sarscov
infect
accordingli
antivir
treatment
durat
appli
patient
infect
merscov
retrospect
cohort
studi
patient
year
old
merscov
pneumonia
saudi
arabia
combin
ribavirin
treatment
continu
day
surviv
increas
significantli
although
differ
reach
statist
signific
surviv
show
posit
trend
treatment
group
also
howev
even
approxim
day
antivir
therapi
merscov
remain
detect
respiratori
secret
patient
week
sinc
clinic
signific
find
unclear
studi
requir
appropri
durat
antivir
treatment
treatment
extens
consid
immun
defici
lead
persist
viral
shed
wherea
patient
show
rapid
recoveri
concern
advers
drug
effect
antivir
treatment
durat
might
shorten
antivir
treatment
gener
recommend
day
pa
consid
physiolog
adapt
pregnanc
pregnant
women
treat
conserv
decis
use
antivir
drug
requir
consider
ethic
issu
consult
obstetr
specialist
aiii
pregnant
women
convent
consid
highrisk
group
progress
sever
diseas
death
case
report
stillbirth
second
trimest
pregnanc
woman
infect
merscov
antivir
drug
recommend
ribavirin
categori
x
safeti
pregnant
women
lopinavirritonavir
type
interferon
categori
c
given
lack
clinic
studi
antivir
treatment
pregnant
women
difficult
recommend
drug
consid
physiolog
adapt
pregnanc
pregnant
women
conserv
treatment
provid
treat
pregnant
women
infect
human
immunodefici
viru
hiv
prefer
proteas
inhibitor
lopinavirritonavir
among
type
interferon
evid
support
safe
use
use
treat
multipl
sclerosi
pregnant
women
although
one
report
show
incid
spontan
abort
increas
pregnant
women
use
statist
signific
differ
incid
control
individu
therefor
use
antivir
drug
consid
comparison
risk
benefit
drug
possibl
antivir
treatment
would
combin
therapi
lopinavirtironavir
case
report
use
pregnant
women
mer
decis
use
antivir
drug
requir
consider
ethic
issu
consult
obstetr
specialist
care
must
taken
prevent
occurr
hemolyt
anemia
use
ribavirin
chang
complet
blood
count
cbc
reticulocyt
haptoglobin
bilirubin
level
monitor
close
hemolyt
anemia
occur
dose
reduct
cessat
consid
aiii
type
interferon
caus
myeloid
dysfunct
cbc
chang
must
close
monitor
anemia
leukopenia
thrombocytopenia
occur
dose
reduct
cessat
consid
biii
patient
infect
sarscov
hemolyt
anemia
reportedli
occur
patient
ribavirin
treatment
could
occur
day
start
treatment
averag
occur
day
start
treatment
mostli
occur
dose
exceed
normal
dose
mg
could
occur
dose
use
treat
merscov
henc
ribavirin
use
chang
hemoglobin
bilirubin
haptoglobin
reticulocyt
level
requir
close
monitor
hemolyt
anemia
occur
dose
reduct
cessat
consid
necessari
use
lopinavirritonavir
instead
ribavirin
could
consid
dose
reduct
requir
case
impair
renal
function
ribavirin
use
recommend
patient
dialysi
sever
renal
dysfunct
due
concern
fatal
hemolyt
anemia
common
advers
effect
ribavirin
includ
bradycardia
hypomagnesemia
hypocalcemia
addit
sinc
ribavirin
show
teratogen
male
femal
patient
use
contracept
month
treatment
fatigu
flulik
symptom
occur
type
interferon
use
case
patient
given
support
care
care
requir
sinc
patient
take
type
interferon
show
anemia
leukopenia
thrombocytopenia
due
bone
marrow
suppress
anemia
occur
ribavirin
dose
first
need
reduc
ceas
administ
combin
still
improv
use
recombin
erythropoietin
consid
leukopenia
thrombocytopenia
occur
interferon
dose
need
reduc
accord
manufactur
recommend
biliti
clinic
trial
shortterm
use
mycophenol
acid
combin
merscov
infect
lower
ec
valu
chloroquin
inhibit
merscov
replic
ec
predict
inhibit
infect
earli
stage
chlorpromazin
suppress
viral
invas
earli
stage
inhibit
clathrinmedi
endocytosi
predict
antivir
effect
inhibit
later
process
loperamid
also
suggest
possibl
treatment
sinc
inhibit
two
coronavirus
low
micromolar
concentr
effect
amiodaron
merscov
infect
confirm
known
inhibit
sarscov
prolifer
postendosom
level
alter
endocyt
pathway
predict
similar
effect
merscov
infect
one
key
function
receptor
host
cell
infect
merscov
transmembran
protein
dipeptidyl
peptidas
adenosin
deaminas
protein
bind
therebi
compet
merscov
bind
confirm
act
antagonist
merscov
infect
vitro
break
incretin
enzymat
function
inhibitor
gliptin
use
hypoglycem
agent
interfer
enzymat
action
therefor
inhibitor
gliptin
may
interfer
merscov
bind
experiment
studi
conduct
date
convalesc
plasma
therapi
could
administ
experiment
patient
sever
merscov
infect
refractori
antivir
drug
biii
appropri
time
convalesc
plasma
therapi
patient
merscov
infect
within
week
diseas
onset
biii
insuffici
evid
ascertain
safeti
efficaci
convalesc
plasma
therapi
patient
merscov
infect
sarscov
treatment
experi
would
help
accord
result
metaanalysi
examin
eight
observ
studi
convalesc
plasma
therapi
patient
sarscov
infect
mortal
rate
lower
patient
given
treatment
major
advers
effect
report
term
convalesc
plasma
administr
time
subgroup
analysi
perform
patient
result
posit
treatment
given
within
day
symptom
onset
also
analysi
patient
sar
hong
kong
treat
convalesc
plasma
treatment
time
significantli
earlier
group
posit
result
compar
group
poor
result
day
vs
day
p
consid
hypothesi
inappropri
antibodi
respons
could
lead
poor
clinic
result
merscov
infect
convalesc
plasma
therapi
could
help
patient
sever
diseas
fact
serum
collect
patient
die
merscov
infect
specif
antibodi
detect
serum
collect
day
infect
convalesc
plasma
therapi
patient
merscov
infect
could
perform
experiment
patient
consent
guardian
consent
case
patient
lack
capac
give
consent
patient
sever
diseas
refractori
antivir
therapi
consid
sarscov
treatment
experi
date
appropri
time
treat
merscov
infect
convalesc
plasma
therapi
like
within
week
diseas
onset
longterm
use
highdos
steroid
caus
advers
effect
develop
opportunist
infect
avascular
necrosi
secondari
bacteri
infect
persist
viral
replic
sinc
efficaci
clearli
proven
sar
routin
use
mer
patient
avoid
howev
state
sever
shock
requir
vasopressor
administr
lowdos
steroid
may
consid
patient
sever
sar
highdos
steroid
often
use
fever
persist
respiratori
failureradiolog
find
worsen
difficult
evalu
efficaci
author
express
opinion
combin
administr
steroid
antivir
drug
would
help
special
case
acut
respiratori
distress
syndrom
caus
sarscov
infect
highdos
steroid
use
patient
merscov
infect
stepdown
dose
methylprednisolon
consid
use
sar
treatment
sinc
lack
evid
efficaci
intraven
immunoglobulin
ivig
routin
use
treatment
mer
recommend
moreov
rare
occas
ivig
lead
acut
renal
failur
thrombosi
although
one
studi
compar
effect
antivir
therapi
ivig
patient
sar
result
inconclus
one
analysi
pneumonia
confirm
patient
south
korean
merscov
infect
epidem
unpublish
data
although
major
case
thought
viral
pneumonia
data
need
show
mani
case
actual
concurr
bacteri
pneumonia
accord
previou
report
case
mer
accompani
virus
parainfluenza
rhinoviru
influenza
viru
herp
simplex
viru
mechanicallyventil
patient
complic
secondari
bacteri
pneumonia
caus
klebsiella
pneumonia
staphylococcu
aureu
acinetobact
spp
antibacteri
treatment
combin
bacteri
pneumonia
determin
accord
patient
clinic
condit
produc
treatment
guidelin
appropri
domest
situat
evid
must
suppli
data
recent
domest
merscov
epidem
howev
domest
clinic
experi
yet
publish
form
academ
paper
could
fulli
reflect
guidelin
futur
variou
studi
publish
clinic
featur
treatment
merscov
south
korea
guidelin
requir
amend
addit
due
lack
suffici
evid
guidelin
mostli
recommend
reflect
opinion
specialist
henc
note
way
absolut
standard
appli
treatment
individu
patient
recommend
may
differ
accord
patient
condit
opinion
clinician
involv
guidelin
reform
addit
latest
evid
suffici
amount
data
accumul
regard
treatment
experi
republ
korea
oversea
treatment
guidelin
compil
support
ksid
ksc
committe
develop
guidelin
receiv
form
payment
relat
develop
herein
influenc
receiv
forprofit
organ
